Impact of Cancer Treatment on Hematological Parameters in Patients with Bladder Cancer
DOI:
https://doi.org/10.36320/ajb/v18.i2.23775Keywords:
Bladder cancer, hematological parameters, chemotherapy, immunotherapy, complete blood countAbstract
One of the most common urological cancers in the world, bladder cancer may affect a number of hematological parameters while being treated. The purpose of this research was to assess how various bladder cancer therapy approaches affected hematological markers. 80 bladder cancer patients (30 pre-treatment and 50 post-treatment) and 30 healthy controls were selected from the Oncology Center at Imam Hussein Hospital in Karbala between October 2025 and March 2026, for a total of 110 Iraqi participants. EDTA-anticoagulated venous blood samples were used to test hematological parameters such as hemoglobin (Hb), red blood cells (RBCs), white blood cells (WBCs), differential WBC count, and platelet count. SPSS version 28 was used for the statistical analysis, which included independent t-tests (P < 0.05) and one-way ANOVA. Patients had considerably lower hemoglobin levels than controls, and after therapy, their RBC, WBC, and platelet counts decreased. Hemoglobin and platelet counts were considerably impacted by treatment duration, but there were no discernible changes between intravesical chemotherapy and immunotherapy. These results show that changes in hematological parameters are linked to bladder cancer and its intravesical treatments, underscoring the need for routine monitoring of complete blood count indices throughout therapy
Downloads
References
1-Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2021 May;71(3):209-49.
2-Richters A, Aben KK, Kiemeney LA. The global burden of urinary bladder cancer: an update. World journal of urology. 2020 Aug;38(8):1895-904.
3-Lenis AT, Lec PM, Chamie K, Mshs MD. Bladder cancer: a review. Jama. 2020 Nov 17;324(19):1980-91.
4-Azam F, Alharbi H, Alshangiti A, Gul AR, Bukhari N, Ouda M, Hussain SA, Ibnshamsah F, AlShangiti A, Hussain SA, Ibnshamsa F. Eligibility criteria for different platinum-based chemotherapy regimens in metastatic urothelial carcinoma. Cureus. 2024 Aug 9;16(8).
5-Wang Q, Zhu SR, Huang XP, Liu XQ, Liu JB, Tian G. Prognostic value of systemic immune-inflammation index in patients with urinary system cancers: a meta-analysis. European Review for Medical & Pharmacological Sciences. 2021 Feb 1;25(3).
6-Daman AW, Antonelli AC, Redelman-Sidi G, Paddock L, Khayat S, Ketavarapu M, Cheong JG, Jurado LF, Benjamin A, Jiang S, Ahimovic D. Microbial cancer immunotherapy reprograms hematopoiesis to enhance myeloid-driven anti-tumor immunity. Cancer Cell. 2025 Aug 11;43(8):1442-59.
7-Hu B, Yang XR, Xu Y, Sun YF, Sun C, Guo W, Zhang X, Wang WM, Qiu SJ, Zhou J, Fan J. Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma. Clinical Cancer Research. 2014 Dec 1;20(23):6212-22.
8-Griebsch I, Shrestha S, Lotan Y, Ng CF, Bottomley A. The Impact of Intravesical Instillations on Quality of Life in Patients with Non-Muscle-Invasive Bladder Cancer: A Systematic Review. Oncology and Therapy. 2025 Nov 13:1-24.
9-Celik M, Polat ME, Karaaslan M, Odabas Ö, Yilmaz FM. Prediction of recurrence using hematologic and urinary markers in intravesical Bacillus calmette Guerin treated bladder cancer. Scientific Reports. 2025 Oct 10;15(1):35415.
10-Warli SM, Andy A, Prapiska FF, Siregar GP, Sihombing B. Poor prognosis of urothelial carcinoma in patients presented with persistent paraneoplastic leukocytosis with anemia. Urology Annals. 2022 Oct 1;14(4):328-31.
11-Vignjević Petrinović S, Jauković A, Milošević M, Bugarski D, Budeč M. Targeting stress erythropoiesis pathways in cancer. Frontiers in Physiology. 2022 May 25;13:844042.
12-Rollin P, Pluskwa B, Artru E, Le Vaslot T, Kartasheva-Ebertz D, Biron D, Bossis M, Onodi F, LeMaoult J, Rouas-Freiss N, Chevalier MF. BCG immunotherapy for bladder cancer triggers systemic and local BCG-specific CD4+ Th1 responses. Iscience. 2026 Feb 20;29(2).
13-Morales-Pacheco M, Valenzuela-Mayen M, Gonzalez-Alatriste AM, Mendoza-Almanza G, Cortés-Ramírez SA, Losada-García A, Rodríguez-Martínez G, González-Ramírez I, Maldonado-Lagunas V, Vazquez-Santillan K, González-Covarrubias V. The role of platelets in cancer: from their influence on tumor progression to their potential use in liquid biopsy. Biomarker Research. 2025 Feb 11;13(1):27.
14-Bozzini C, Busti F, Marchi G, Vianello A, Cerchione C, Martinelli G, Girelli D. Anemia in patients receiving anticancer treatments: focus on novel therapeutic approaches. Frontiers in oncology. 2024 Apr 2;14:1380358.
15-Nebioğlu A, Turhan A, Başaranoğlu M, Bozlu M, Akbay E. Prognostic Significance of Hemogram Parameters in Non-Muscle Invasive Bladder Cancer: A Comprehensive Retrospective Analysis. Medicina. 2025 Dec 26;62(1):51.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 aliaam alghafil, Dr. Mohsin Kazem Hassan
This work is licensed under a Creative Commons Attribution 4.0 International License.
which allows users to copy, create extracts, abstracts, and new works from the Article, alter and revise the Article, and make commercial use of the Article (including reuse and/or resale of the Article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made and the licensor is not represented as endorsing the use made of the work.
